Rapid growth spurs McCann Health to recruit ex-Publicis HR exec as its first global chief talent officer

McCann Health hired Geline Midouin from digital agency  360i as global chief talent officer after 2016 rapid growth.

McCann Health has scooped Geline Midouin from digital agency 360i to serve as its first-ever global chief talent officer—a role she previously filled for more than five years at Publicis Healthcare.

Now, the McCann post marks a return to the healthcare industry for Midouin, a veteran human resources executive. McCann Health noted in an announcement that the new role was created after a year of rapid growth for the agency that included new business wins from GlaxoSmithKline, Bayer, Gilead and Janssen.

“I will be partnering with the leadership team to ensure that we attract and build high-performing teams that can drive innovation, collaboration and creativity,” Midouin said via email, adding that she’s also looking to create “transformational leaders.”

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

McCann Health Global CEO John Cahill in a statement praised Midouin for “her skills and depth of experience in human capital management, modern concepts in talent deployment and ways of working, and a rich appreciation of the value of a ‘people first’ approach that enables talent to do great work.”

Before Midouin joined Publicis, she spent 10 years at NBCUniversal in a variety of senior human resources roles, and worked as well at Arthur Andersen and Goldman Sachs.

The new global chief talent officer role at McCann Health follows another new executive post addition—chief growth officer for McCann Health North America—created in February.

Suggested Articles

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.